Trial Analysis
Benefit-risk balance of S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)
READ MORE →
Innovative Trial Design
OSE Immunotherapeutics and One2Treat jointly won the Innovation award for Endpoint Design in the 2025 Clinical Trials Arena Excellence Awards
READ MORE →
Trial Designs
OSE Immunotherapeutics: One2Treat Voice for outcomes prioritization in ARTEMIA
READ MORE →
Innovative Trial Design
Benefit-risk analyses in cancer treatment
READ MORE →
Holistic Data Analysis
Improving knowledge about the treatment effect
READ MORE →
Innovative Trial Design
Design a patient-centric trial & avoid a demonstration of “non-inferiority”
READ MORE →
Market Access And HTA
Benefit-risk assessment for metastatic pancreatic cancer
READ MORE →
Holistic Data Analysis
Mid-size US biotech company, phase 3 oncology trial
READ MORE →
Innovative Trial Design
Using more information for fewer patients.
READ MORE →
Shared Decision Making
Including patient voice in therapeutic choices in breast cancer care.
READ MORE →